Phase II results cognitive impairment schizophrenia

Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophreniaResults presented at the 33rd ECNP Congress from a 12-week, placebo-controlled Phase II trial demonstrated BI 425809 has met its primary endpoint1,2Trial results, together with an ongoing combination Phase II study of BI 425809 and adjunctive computerized cognitive training, add to the body of evidence for Boehringer Ingelheim ’s schizophrenia research program3Cognitive impairment associated with schizophrenia (CIAS) has a significant negative impact on daily functioning and remains a focus for Boehringer Ingelheim ’s research across several neuropsychiatric disorders
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news